Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial.
Thyroid
; 32(10): 1184-1192, 2022 Oct.
Article
in En
| MEDLINE
| ID: mdl-35658604
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Thyroid Neoplasms
/
Adenocarcinoma
/
Melanoma
Type of study:
Clinical_trials
Limits:
Adolescent
/
Adult
/
Humans
Language:
En
Journal:
Thyroid
Journal subject:
ENDOCRINOLOGIA
Year:
2022
Document type:
Article
Affiliation country:
United States